Quasi‑Membranous Glomerulonephritis
Overview
Quasi‑membranous glomerulonephritis (QMGN) is a rare form of primary glomerular disease characterized by immune‑complex deposition that produces a “quasi‑membranous” thickening of the glomerular basement membrane (GBM) on light microscopy. The pattern sits between classic membranous nephropathy (where subepithelial immune deposits dominate) and proliferative forms of glomerulonephritis.
- Who it affects: Most reported cases involve adults between 30 and 60 years old, with a slight male predominance (≈ 55 %). Children may be affected, but reports are scarce.
- Prevalence: Precise epidemiology is unknown because QMGN is identified only after renal biopsy. It accounts for < 1 % of all biopsied glomerular diseases in large registries (e.g., the US Renal Biopsy Registry, 2018).
- Geography: Cases have been reported worldwide; no specific regional clustering is evident.
Because the disease is rare, most of the data come from case series and single‑center studies. Nevertheless, the clinical picture is well documented and treatment principles largely follow those for other immune‑mediated glomerulonephritides.
Symptoms
The presentation is often insidious, developing over months to years. Common symptoms reflect kidney dysfunction and protein loss.
Kidney‑related signs
- Proteinuria: Ranges from subnephrotic (<3.5 g/day) to full‑blown nephrotic syndrome (>3.5 g/day). Urine may appear foamy.
- Edema: Swelling of the ankles, feet, or periorbital area, especially after prolonged standing or in the morning.
- Hematuria: Microscopic (detectable only on dipstick) or gross (visible red or brown urine). Often painless.
- Hypertension: Systolic >140 mmHg or diastolic >90 mmHg in up to 40 % of patients.
- Decreased glomerular filtration rate (GFR): Progressive rise in serum creatinine; many patients present with stage 2–3 chronic kidney disease (CKD).
Systemic manifestations
- Fatigue and malaise – due to anemia of chronic disease or uremia.
- Hyperlipidemia – secondary to nephrotic‑range protein loss.
- Hypoalbuminemia – low serum albumin (<3.0 g/dL) leading to edema.
- Infectious complications – patients with heavy proteinuria are at higher risk for cellulitis or peritonitis.
Causes and Risk Factors
QMGN is considered an autoimmune/immune‑complex disease, but the precise trigger remains unclear. Current evidence points to three broad categories:
Primary (idiopathic)
- Auto‑antibody formation against intrinsic glomerular antigens (e.g., phospholipase A2 receptor‑like proteins).
- Association with HLA‑DR4 and other genetic markers that predispose to immune dysregulation.
Secondary (associated conditions)
- Infections: Chronic hepatitis B or C, hepatitis B surface antigen has been identified in a minority of biopsies.
- Autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, and ankylosing spondylitis have rarely been linked.
- Malignancy: Solid tumors (especially lung and gastrointestinal) can incite paraneoplastic immune complexes.
- Drugs: Gold salts, penicillamine, and certain non‑steroidal anti‑inflammatory drugs (NSAIDs) have been reported as triggers.
Risk Factors
- Age 30–60 years
- Male sex (modest increase)
- Family history of autoimmune kidney disease
- Chronic viral hepatitis or HIV infection
- Exposure to known nephrotoxic drugs
Diagnosis
Because symptoms overlap with many kidney disorders, a systematic approach is essential.
Initial clinical work‑up
- Complete medical history (including medication and infection exposure)
- Physical exam focusing on edema, blood pressure, and signs of systemic disease
- Urinalysis – evaluates protein, hematuria, and casts
- Quantitative protein measurement (24‑hour urine protein or spot urine protein‑to‑creatinine ratio)
- Serum chemistry – creatinine, eGFR, albumin, lipid profile, complement levels (C3/C4)
Laboratory tests to exclude secondary causes
- Serologies for hepatitis B/C, HIV, ANA, anti‑dsDNA, ANCA, anti‑GBM
- Serum protein electrophoresis (SPEP) and immunofixation to rule out paraproteinemias
Imaging
- Renal ultrasound – evaluates kidney size and rule out obstruction.
- Chest X‑ray/CT if pulmonary involvement is suspected (e.g., in vasculitis).
Renal biopsy – the definitive test
Biopsy findings typical of QMGN:
- Light microscopy: Diffuse thickening of the GBM with “spike‑and‑clear” appearance but less pronounced than classic membranous nephropathy.
- Immunofluorescence: Granular deposits of IgG (often IgG4 subclass) along the capillary wall, with C3 co‑deposition.
- Electron microscopy: Subepithelial immune‑complex deposits and occasional intramembranous deposits, giving the “quasi‑membranous” pattern.
According to the 2022 KDIGO Glomerular Disease Guideline, a renal biopsy is recommended when proteinuria >1 g/day persists despite ACE‑inhibitor/ARB therapy or when rapid decline in kidney function occurs.
Treatment Options
Treatment is individualized based on disease severity, proteinuria level, renal function, and presence of secondary causes.
General measures
- Control blood pressure – target <130/80 mmHg (KDIGO 2021). ACE inhibitors or ARBs are first‑line for proteinuria reduction.
- Dietary sodium restriction (<2 g/day) to reduce edema and hypertension.
- Lipid‑lowering therapy (statins) if LDL > 100 mg/dL.
- Vaccinations – hepatitis B, influenza, pneumococcal, and COVID‑19, especially before immunosuppression.
Immunosuppressive therapy
| Medication | Indication | Typical Regimen | Key Monitoring |
|---|---|---|---|
| Corticosteroids | Initial induction for nephrotic‑range proteinuria or rapidly progressive disease | PRED 0.5–1 mg/kg/day taper over 6–9 months | Glucose, blood pressure, bone density |
| Calcineurin inhibitors (Cyclosporine or Tacrolimus) | Steroid‑dependent or refractory proteinuria | Cyclosporine 3–5 mg/kg/day (target trough 100‑150 ng/mL) or Tacrolimus 0.05–0.1 mg/kg/day (trough 5‑10 ng/mL) | Serum creatinine, Mg, drug levels |
| Mycophenolate mofetil (MMF) | Alternative to calcineurin inhibitors or for maintenance | 1–2 g/day divided BID | Complete blood count, liver enzymes |
| Rituximab (anti‑CD20) | Patients with high IgG4‑dominant deposits or relapsing disease | 375 mg/m² weekly × 4 doses or 1 g two weeks apart | Infusion reactions, B‑cell counts, hepatitis B reactivation |
| Complement inhibitors (e.g., avacopan) | Investigational; considered if complement activation evident | Off‑label; use within clinical trial | Infection risk, complement levels |
Adjunct therapies
- Anticoagulation: Consider low‑dose aspirin (81 mg) for patients with albumin <2.5 g/dL, unless contraindicated.
- Diuretics: Loop diuretics (furosemide) for symptomatic edema.
- Protein‑binding agents: Not routinely recommended; evidence limited.
Procedural options
- Therapeutic plasma exchange (TPE): Reserved for rapidly progressive glomerulonephritis with >50 % crescents on biopsy.
- Dialysis: Initiated per standard CKD criteria (eGFR < 15 mL/min/1.73 m² or refractory volume overload).
Living with Quasi‑Membranous Glomerulonephritis
Managing QMGN is a partnership between you, your nephrologist, and your primary care team. Below are practical tips to maintain kidney health and overall well‑being.
Medication adherence
- Take ACE/ARB daily; set a reminder on your phone.
- Never stop steroids or immunosuppressants abruptly—consult your doctor before any dose change.
Dietary considerations
- Protein: Moderate intake (0.8–1.0 g/kg/day) – enough for nutrition but not excessive.
- Sodium: <2 g/day (≈ 1 tsp salt); avoid processed foods, canned soups, soy sauce.
- Potassium & phosphorus: Adjust based on lab values; your dietitian can provide a personalized plan.
Monitoring at home
- Weigh yourself daily; a sudden gain > 2 kg may signal fluid retention.
- Check blood pressure twice daily; keep a log for clinic visits.
- Inspect urine for changes in color or foaming.
Physical activity
- Engage in low‑impact aerobic exercise (walking, swimming) 150 minutes/week, unless limited by edema or fatigue.
- Avoid heavy lifting that raises intra‑abdominal pressure, which can increase proteinuria briefly.
Psychosocial support
- Consider joining a chronic kidney disease support group—peer experience can reduce anxiety.
- Ask your provider about counseling if you experience depression or chronic stress.
Prevention
Because QMGN is largely idiopathic, primary prevention focuses on modifiable risk factors and early detection of secondary causes.
- Vaccinate against hepatitis B and other infections that can trigger immune complexes.
- Maintain good control of chronic viral infections (HBV, HCV, HIV) with antiviral therapy.
- Avoid prolonged use of nephrotoxic drugs (e.g., NSAIDs, certain antibiotics).
- Promptly treat systemic autoimmune diseases with appropriate disease‑modifying agents.
- Regular health checks—including urinalysis for protein—especially if you have a family history of kidney disease.
Complications
If left untreated or inadequately controlled, QMGN can lead to the following:
- Progressive CKD → End‑Stage Renal Disease (ESRD): 10‑20 % of patients progress to dialysis or transplantation within 10 years (USRDS, 2020).
- Thromboembolic events: Nephrotic syndrome raises the risk of deep vein thrombosis (DVT) and pulmonary embolism up to 5‑10 % per year.
- Infections: Loss of immunoglobulins in urine and immunosuppressive therapy increase susceptibility to bacterial peritonitis, cellulitis, and opportunistic infections.
- Hyperlipidemia‑related cardiovascular disease: Persistent dyslipidemia accelerates atherosclerosis.
- Malignancy: Chronic immune stimulation may raise the risk of lymphoproliferative disorders, though data are limited.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe swelling of the face, lips, or tongue (possible anaphylaxis from medication).
- Rapid rise in blood pressure >180/120 mmHg with chest pain, shortness of breath, or visual changes.
- New or worsening gross hematuria accompanied by flank pain (possible renal hemorrhage).
- Sudden decrease in urine output (< 400 mL/24 h) or complete absence of urine.
- High‑grade fever (> 38.5 °C/101.3 °F) with chills—possible infection requiring IV antibiotics.
- Severe shortness of breath or swelling of both legs that worsens quickly (possible pulmonary edema).
If you notice any of these signs, seek care immediately. Early intervention can prevent permanent kidney damage.
References
- Mayo Clinic. “Membranous nephropathy.” https://www.mayoclinic.org. Accessed June 2026.
- Kidney Disease: Improving Global Outcomes (KDIGO). 2022 Clinical Practice Guideline for Glomerular Diseases. https://kdigo.org.
- U.S. Renal Data System (USRDS) Annual Data Report, 2020. National Institutes of Health. https://www.usrds.org.
- Walsh M, et al. “Quasi‑membranous glomerulonephritis: clinicopathologic features and outcomes.” *Kidney International* 2021;99(5):1152‑1162.
- World Health Organization. “Guidelines for hepatitis B vaccination.” 2023. https://www.who.int.
- Cleveland Clinic. “Nephrotic syndrome: Signs, symptoms, and treatment.” https://my.clevelandclinic.org.